Warner, Evan W.
Van der Eecken, Kim
Murtha, Andrew J.
Kwan, Edmond M. http://orcid.org/0000-0002-7053-680X
Herberts, Cameron http://orcid.org/0000-0002-9929-8374
Sipola, Joonatan
Ng, Sarah W. S. http://orcid.org/0000-0002-7647-6940
Chen, Xinyi E.
Fonseca, Nicolette M.
Ritch, Elie
Schönlau, Elena
Bernales, Cecily Q.
Donnellan, Gráinne
Munzur, Aslı D.
Parekh, Karan
Beja, Kevin
Wong, Amanda
Verbeke, Sofie
Lumen, Nicolaas
Van Dorpe, Jo
De Laere, Bram
Annala, Matti
Vandekerkhove, Gillian http://orcid.org/0000-0001-5606-0908
Ost, Piet http://orcid.org/0000-0002-2203-4848
Wyatt, Alexander W. http://orcid.org/0000-0003-2399-0329
Article History
Received: 30 September 2022
Accepted: 15 November 2023
First Online: 4 January 2024
Competing interests
: E.W.W. is an employee at Guardant Health (although only contributed to this article before commencing employment with Guardant Health in April 2023). E.M.K. has consulted or served in an advisory role for Astellas Pharma, Janssen and Ipsen, received travel funding from Astellas Pharma, Pfizer, Ipsen and Roche, received honoraria from Janssen, Ipsen, Astellas Pharma and Research Review and research funding from Astellas Pharma (institutional) and AstraZeneca. M.A. is a shareholder in Fluivia. The laboratory of N.L. has research funding from Bayer (Inst) and Janssen (Inst) and has received travel funding from Ipsen (Inst). P.O. has consulted or served in an advisory role for Janssen-Cilag, Bayer, Astellas Pharma, Curium Pharma, Telix Pharmaceuticals and Novartis and has received travel funding from Ferring. The laboratory of P.O. has received research funding from Varian Medical Systems (Inst) and Bayer (Inst). A.W.W. has served on advisory boards and/or received honoraria from AstraZeneca, Astellas, Bayer, EMD Serono, Janssen, Merck and Pfizer. The laboratory of A.W.W. has a contract research agreement with ESSA Pharma. All other authors declare no competing interests.